91-105 of 917
Clinical Perspective on New Therapies in Resistant Hypertension
CardiologyClinical Perspective on New Therapies in Resistant Hypertension
Clyde W. Yancy, MD
Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Heart MattersRethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Susan Davis
Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Heart MattersTargeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Heart MattersNavigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Jun-ichi Abe
Exploring Patient Perspectives on Genetic Testing for ATTR-CM
On the Frontlines of ATTR-CMExploring Patient Perspectives on Genetic Testing for ATTR-CM
Shelina Ramnarine, PhD
Quan Bui, MD
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
CardiologyPrecision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Ahmad Masri, MD, MS
- advertisement
The Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
CardiologyThe Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
Erin Michos
DARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
CardiologyDARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
Clyde W. Yancy, MD
DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
CardiologyDECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
Christopher Wong
POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
CardiologyPOLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
Ambarish Pandey, MD
The LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options
CardiologyThe LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options
Prof. Kausik Ray
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
CardiologyADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
Jung-Sun Kim, MD, PhD
- advertisement
OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
CardiologyOCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
Atul Verma, MD
PREVENT vs PCE: Refining ASCVD Risk Prediction in Statin-Treated Populations
Heart MattersPREVENT vs PCE: Refining ASCVD Risk Prediction in Statin-Treated Populations
The LDL-C Gap in Statin-Treated Patients: A Population-Level Problem with Economic Consequences
Heart MattersThe LDL-C Gap in Statin-Treated Patients: A Population-Level Problem with Economic Consequences
